Thus, this single-cell analysis across patients identified AP-1 induction as a predictor of vortioxetine efficacy and validated the glioblastoma-specific therapeutic convergence of NADs on AP-1/BTG-driven tumor suppression across modalities and patient heterogeneity. Here, FOS is linked to glioblastoma.